Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sintilimab Plus Chemotherapy as Induction Therapy for Unresectable Stage IIIC NSCLC

NCT07603661 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT07603661
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07603661 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sintilimab Plus Chemotherapy as Induction Therapy for Unresectable Stage IIIC NSCLC
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
June 1, 2026
Completion date
June 1, 2029
Enrollment
33 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer